Swedish model for PSA testing has little effect on mortality

January 26, 2015

The spontaneous PSA testing that has been applied in Sweden in recent decades has only had a marginal effect on mortality. An organized screening focused on those who have the most to gain would, however, reduce the risk of dying from prostate cancer by over 40 percent. This is shown by studies at the University of Gothenburg.

In Sweden, national programs for of both cervical cancer (Pap smear tests) and breast cancer (mammography) are applied. A corresponding program for the screening of prostate cancer does not exist.

Opportunistic screening

Many men instead have PSA tests on their own initiative, so-called opportunistic screening. However, there is no national recommendation on how such a test program should be formulated.

In several large studies, researchers at the Sahlgrenska Academy, University of Gothenburg, have tested organized PSA screening of 10,000 randomly chosen men in the Gothenburg region, and compared with the outcome in opportunistic screening.

Reduces risk of dying

The studies show that an organized test program both identifies more cancer cases in an early, curable phase and sharply reduces the risk of dying:

  • In the group of men that was offered organized PSA screening, the risk of dying from prostate cancer decreased by 42 percent. In the group that was exposed to opportunistic screening, only a marginally reduced mortality was seen.
  • Converted to a calculation example, one prostate cancer death per 13 men diagnosed with prostate cancer was prevented in organized screening compared with one prostate cancer death per 23 diagnosed men prevented in opportunistic screening.

Small effects

"The opportunistic PSA screening that we have used in Sweden for 20 years is simply not effective, and has only marginally reduced the risk of men dying from the disease," says Rebecka Arnsrud Godtman who is publishing the studies in her dissertation.

The opportunistic screening also leads to a larger proportion of men being unnecessarily diagnosed with . Besides the mental strain from being diagnosed with cancer, these men are at risk of living with the side-effects of a treatment for the rest of their lives, without actually getting any positive effects, according to Rebecka Arnsrud Godtman.

Active surveillance

The Gothenburg researchers' conclusion is that the PSA screening in Sweden should take place in an organized program where men are regularly invited for tests. Screening should start at a relatively young age, around 50, and take place with frequent checks. To minimize the risks of overdiagnosis, older men and men with other diseases should not undergo PSA screening.

The risk of overtreatment can be reduced through so-called , where diagnosed are under careful observation and only treated if the tumor shows signs of becoming more aggressive. According to the dissertation, a full 60 percent of the tumors found in organized PSA screening can be handled with active monitoring.

Explore further: Active surveillance can reduce suffering among men with prostate cancer

More information: Link to dissertation: gupea.ub.gu.se/handle/2077/36913

Related Stories

Active surveillance can reduce suffering among men with prostate cancer

November 2, 2012
With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 ...

Organized screening for prostate cancer does more harm than good

September 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...

Prostate cancer mortality benefit seen for family Hx-based screens

January 19, 2015
(HealthDay)—Screening white men with a family history of prostate cancer appears to be associated with a decrease in prostate cancer-specific mortality, according to a study published in the January issue of The Journal ...

Four reasons I won't have a prostate cancer blood test

December 11, 2014
Cancer Council Australia and the Prostate Cancer Foundation of Australia yesterday released new draft guidelines to help GPs counsel men who ask about prostate cancer tests. They advise GPs to explain the pros and cons of ...

Alternative PSA screening strategies could reduce harm

February 5, 2013
(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according ...

PSA-testing and early treatment decreases risk of prostate cancer death

March 10, 2014
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online today in Journal of the National Cancer Institute by researchers from ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.